Evidence map›Paper›PMID 41281761›Full record

ArticleInternational journal of biological sciences2025

Targeting FTL regulates ferroptosis and remodels lymph node metastasis microenvironment in esophageal squamous cell carcinoma.

Shuyue Zheng, Yunzhi Liu, Baifeng Zhang, Jiao Huang, Xiaona Fang, Cuicui Huang, Lanqi Gong, Jie Luo, Yuma Yang, Shan Liu and 7 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shuyue ZhengDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Yunzhi LiuDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Baifeng ZhangDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Jiao HuangDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Xiaona FangState Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Cuicui HuangDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Lanqi GongDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Jie LuoDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Yuma YangDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Shan LiuDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Ching Ngar WongDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Jinlin HuangDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Shanshan LiDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Yanan TanDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
Qingyun ChenMedical Research Institute, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, Guangdong, 510080, China.
Yanru QinDepartment of Clinical Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Xin-Yuan GuanDepartment of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than half of Esophageal squamous cell carcinoma (ESCC) patients are at an advanced stage when first diagnosed, thus they do not benefit much from radical surgery. Single-cell RNA sequencing (scRNA-seq) data from patients with ESCC lymph node metastasis in our laboratory implied that ferroptosis might play an important role in ESCC metastasis. Ferroptosis was found to be a shared specific pathway between ESCC and adjacent non-tumor tissue, as well as between ESCC lymph node metastasis and adjacent non-tumor tissue, of which FTL was selected as the pivotal target gene within this common pathway. Bioinformatic analyses showed that FTL was highly expressed in both primary and metastatic sites than normal, and patients with high expression had poor prognosis, and its function was related to macrophages in TME. Functional studies have shown that FTL promoted tumor growth, tolerated oxidative stress, reduced the sensitivity of ESCC cells to ferroptosis, facilitated epithelial-mesenchymal transition (EMT) and recruited more macrophages to promote metastasis. Mechanism studies have shown that FTL promotes ESCC development and metastasis via NRF2 pathway and inhibits ferroptosis via NCOA4 protein.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaFerroptosisAnimalsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiceTumor Microenvironmentesophageal squamous carcinomaferroptosismetastasistumor microenvironment

Identifiers

PMID41281761
PMCPMC12631076

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.